Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model
ClinicalTrials.gov study NCT03263663. IPD Sharing: YES. Countries: 1. Publications: 0.
Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).
ClinicalTrials.gov study NCT06227897. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT06838273. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT06967155. IPD Sharing: NO. Countries: 1. Publications: 0.
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
ClinicalTrials.gov study NCT04830826. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
ClinicalTrials.gov study NCT06652048. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
ClinicalTrials.gov study NCT03856697. IPD Sharing: NO. Countries: 1. Publications: 0.
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
ClinicalTrials.gov study NCT04181060. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
ClinicalTrials.gov study NCT06362980. IPD Sharing: NO. Countries: 1. Publications: 0.
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
ClinicalTrials.gov study NCT06067776. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
ClinicalTrials.gov study NCT07343479. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment
ClinicalTrials.gov study NCT06095934. IPD Sharing: NO. Countries: 1. Publications: 0.
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
ClinicalTrials.gov study NCT04545710. IPD Sharing: NO. Countries: 1. Publications: 0.
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
ClinicalTrials.gov study NCT04500704. IPD Sharing: NO. Countries: 1. Publications: 0.
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
ClinicalTrials.gov study NCT01665417. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
ClinicalTrials.gov study NCT00298064. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
ClinicalTrials.gov study NCT06383728. IPD Sharing: NO. Countries: 1. Publications: 0.
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
ClinicalTrials.gov study NCT02748707. IPD Sharing: NO. Countries: 1. Publications: 0.
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
ClinicalTrials.gov study NCT06537297. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
ClinicalTrials.gov study NCT07109531. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.